These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 28497760)

  • 21. Antimicrobial proteins: intestinal guards to protect against liver disease.
    Hendrikx T; Schnabl B
    J Gastroenterol; 2019 Mar; 54(3):209-217. PubMed ID: 30392013
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of the gut microbiota in NAFLD.
    Leung C; Rivera L; Furness JB; Angus PW
    Nat Rev Gastroenterol Hepatol; 2016 Jul; 13(7):412-25. PubMed ID: 27273168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intestinal Microbiota, Lipids, and the Pathogenesis of Intestinal Failure-Associated Liver Disease.
    Lee WS; Sokol RJ
    J Pediatr; 2015 Sep; 167(3):519-26. PubMed ID: 26130113
    [No Abstract]   [Full Text] [Related]  

  • 24. [Gut-liver axis: How intestinal bacteria affect the liver].
    Konturek PC; Harsch IA; Konturek K; Schink M; Zopf Y
    MMW Fortschr Med; 2018 Nov; 160(Suppl 5):11-15. PubMed ID: 30367438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liver-Microbiome Axis in Health and Disease.
    Adolph TE; Grander C; Moschen AR; Tilg H
    Trends Immunol; 2018 Sep; 39(9):712-723. PubMed ID: 29843959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.
    Kirpich IA; Marsano LS; McClain CJ
    Clin Biochem; 2015 Sep; 48(13-14):923-30. PubMed ID: 26151226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Intestinal Microbiome in Nonalcoholic Fatty Liver Disease.
    Puri P; Sanyal AJ
    Clin Liver Dis; 2018 Feb; 22(1):121-132. PubMed ID: 29128052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota.
    Doulberis M; Kotronis G; Gialamprinou D; Kountouras J; Katsinelos P
    Metabolism; 2017 Jun; 71():182-197. PubMed ID: 28521872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of non-steroidal anti-inflammatory drugs on intestinal permeability and nonalcoholic fatty liver disease.
    Utzeri E; Usai P
    World J Gastroenterol; 2017 Jun; 23(22):3954-3963. PubMed ID: 28652650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Indoles: metabolites produced by intestinal bacteria capable of controlling liver disease manifestation.
    Hendrikx T; Schnabl B
    J Intern Med; 2019 Jul; 286(1):32-40. PubMed ID: 30873652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Probiotics in Pediatric Liver Disease.
    Miloh T
    J Clin Gastroenterol; 2015; 49 Suppl 1():S33-6. PubMed ID: 26447962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibiotic perturbation of the murine gut microbiome enhances the adiposity, insulin resistance, and liver disease associated with high-fat diet.
    Mahana D; Trent CM; Kurtz ZD; Bokulich NA; Battaglia T; Chung J; Müller CL; Li H; Bonneau RA; Blaser MJ
    Genome Med; 2016 Apr; 8(1):48. PubMed ID: 27124954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gut microbiota-mediated generation of saturated fatty acids elicits inflammation in the liver in murine high-fat diet-induced steatohepatitis.
    Yamada S; Kamada N; Amiya T; Nakamoto N; Nakaoka T; Kimura M; Saito Y; Ejima C; Kanai T; Saito H
    BMC Gastroenterol; 2017 Nov; 17(1):136. PubMed ID: 29187142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How our understanding of the microbiome has changed the way we look at liver diseases.
    Adolph TE; Effenberger M; Tilg H
    Biomark Med; 2018 Nov; 12(11):1203-1206. PubMed ID: 30444134
    [No Abstract]   [Full Text] [Related]  

  • 36. The gut microbiota of nonalcoholic fatty liver disease: current methods and their interpretation.
    van Best N; Jansen PL; Rensen SS
    Hepatol Int; 2015 Jul; 9(3):406-15. PubMed ID: 26067771
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NAFLD, Helicobacter species and the intestinal microbiome.
    Castaño-Rodríguez N; Mitchell HM; Kaakoush NO
    Best Pract Res Clin Gastroenterol; 2017 Dec; 31(6):657-668. PubMed ID: 29566909
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intestinal Failure-Associated Liver Disease.
    Pironi L; Sasdelli AS
    Clin Liver Dis; 2019 May; 23(2):279-291. PubMed ID: 30947877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gut Microbiota in Liver Disease: What Do We Know and What Do We Not Know?
    Jiang L; Schnabl B
    Physiology (Bethesda); 2020 Jul; 35(4):261-274. PubMed ID: 32490750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The intestinal microbiome and metabolic diseases : From obesity to diabetes and nonalcoholic steatohepatitis].
    Bischoff SC
    Internist (Berl); 2017 May; 58(5):441-448. PubMed ID: 28432400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.